Book description
Filling an obvious gap in the scientific literature, this
practice-oriented reference is the first to tie together the working
knowledge of large
screening centers in the pharmaceutical and biotechnological field. It
spans the entire fi eld of this emerging discipline, from compound
acquisition to collection optimization for specific purposes, to
technology and quality control. In so doing, it applies two decades of
expertise gathered by several large pharmaceutical companies to current
and future challenges in high-throughput screening. With its treatment
of libraries of small molecules as well as biobanks containing
biomolecules, microorganisms and tissue samples, this reference is
universally applicable for any molecular scientist involved in a large
screening program. Mark Wigglesworth manages the UK Lead Optimization
area of Sample Management Technologies for GlaxoSmith-Kline. Over the
past 10 years Mark has managed large and small compound stores, assay
ready plate production and compound set provision, as well as
interacting with many areas of drug discovery. Additionally, he has led
several drug discovery programs and overseen multiple screening
platforms providing structure activity relationship data within
GlaxoSmithKline?s screening organizations.
Now a freelance business consultant, Terry Wood retired in 2011 as the
manager of the Liquid Store Centre of Emphasis at Pfizer?s world-wide
R&D department, based in Sandwich (UK). He has been involved in the
high-throughput screening process for the whole of his 25 year career
with Pfizer. This has given him a first hand and broad knowledge about
the challenges and caveats of assay design, development and
prosecution. His prime responsibility focused on the management of
Pfizer?s extensive compound file, using a range of automated systems for
sample preparation, storage and delivery.
